Abstract
Hypertension and atrial fibrillation are the most common cardiovascular risk factors and clinically significant arrhythmia, respectively. These conditions frequently coexist and their prevalence increases rapidly with aging.
Despite several different risk factors and clinical conditions predisposing to hypertension for its high prevalence in the population is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes at the level of left ventricle and or atrium, neurohormonal activation, arterial stiffness, etc.) can contribute to the onset of atrial fibrillation. Some antihypertensive treatments have been shown to contribute to reduce the risk of new-onset atrial fibrillation.
Atrial fibrillation is a major risk factor for stroke, which is further increased in the presence of hypertension. For this reason, hypertension is included as a major risk factor in the available models for the risk stratification and the prevention of thromboembolism in patients with atrial fibrillation. In this article we will review the relationship between atrial fibrillation and hypertension, looking at the possible specific indications of the antithrombotic treatment with new classes of anticoagulants in the prevention of thromboembolic events in hypertensive patients with atrial fibrillation.
Keywords: Hypertension, atrial fibrillation, vitamin K antagonists, new oral anticoagulants.
Current Pharmaceutical Design
Title:Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants
Volume: 20 Issue: 39
Author(s): Lorenzo Ghiadoni, Stefano Taddei and Agostino Virdis
Affiliation:
Keywords: Hypertension, atrial fibrillation, vitamin K antagonists, new oral anticoagulants.
Abstract: Hypertension and atrial fibrillation are the most common cardiovascular risk factors and clinically significant arrhythmia, respectively. These conditions frequently coexist and their prevalence increases rapidly with aging.
Despite several different risk factors and clinical conditions predisposing to hypertension for its high prevalence in the population is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes at the level of left ventricle and or atrium, neurohormonal activation, arterial stiffness, etc.) can contribute to the onset of atrial fibrillation. Some antihypertensive treatments have been shown to contribute to reduce the risk of new-onset atrial fibrillation.
Atrial fibrillation is a major risk factor for stroke, which is further increased in the presence of hypertension. For this reason, hypertension is included as a major risk factor in the available models for the risk stratification and the prevention of thromboembolism in patients with atrial fibrillation. In this article we will review the relationship between atrial fibrillation and hypertension, looking at the possible specific indications of the antithrombotic treatment with new classes of anticoagulants in the prevention of thromboembolic events in hypertensive patients with atrial fibrillation.
Export Options
About this article
Cite this article as:
Ghiadoni Lorenzo, Taddei Stefano and Virdis Agostino, Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants, Current Pharmaceutical Design 2014; 20 (39) . https://dx.doi.org/10.2174/1381612820666140417100251
DOI https://dx.doi.org/10.2174/1381612820666140417100251 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of Thrombospondin-1 (N700S) and Thrombospond in-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians
Current Pharmaceutical Biotechnology Antioxidant Activity and Chemical Components as Potential Anticancer Agents in the Olive Leaf (Olea europaea L. cv Leccino.) Decoction
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Canonical Wnt/Beta-Catenin Signaling Network as Emerging Signaling Cascade for Therapeutic Intervention in Chronic Renal Disease
Current Drug Targets Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Necrotizing Enterocolitis: Clinical Features, Histopathological Characteristics, and Genetic Associations
Current Pediatric Reviews Protein Kinase C Inhibitors in the Treatment of Diabetic Retinopathy. Review
Current Pharmaceutical Biotechnology Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Cardiovascular Risk Factors: Does Sex Matter?
Current Vascular Pharmacology Smad3-Mediated Signals Showing Similarities and Differences Between Epithelial and Mesenchymal Cells in Human Chronic Liver Diseases
Current Enzyme Inhibition Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Acute and Sub-acute Oral Toxicity Assessment of a Standardized Polyherbal Preparation POL-6 in Rats
The Natural Products Journal Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases
Current Medicinal Chemistry Selective Neuronal Nitric Oxide Synthase Inhibitors
Current Topics in Medicinal Chemistry Small RNAs Play Big Roles: MicroRNAs in Diabetic Wound Healing
Current Molecular Medicine